FX.co ★ Shattuck Labs' SL-172154 Granted FDA's Orphan Drug Designation For Treatment Of AML

Shattuck Labs, Inc. (STTK) announced on Monday that the FDA has granted orphan drug designation to their leading clinical candidate, SL-172154, for the treatment of Acute Myeloid Leukemia (AML).

The company also anticipates presenting additional data from the Phase 1B dose expansion clinical trial of SL-172154 in combination with azacitidine. This trial focuses on frontline treatment for higher-risk myelodysplastic syndromes and TP53m AML patients and will be showcased at the European Hematology Association 2024 Congress via a poster presentation.

Acute Myeloid Leukemia is a type of cancer that impacts the blood and bone marrow, characterized by an excessive proliferation of immature white blood cells.